Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.32 USD | -0.85% | -1.02% | -39.41% |
Apr. 18 | Neogen Corporation Forms Genomics Relationship with Performance Food Group | CI |
Apr. 15 | Piper Sandler Adjusts Price Target on Neogen to $17 From $19, Maintains Neutral Rating | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company has insufficient levels of profitability.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-39.41% | 2.69B | C | ||
-3.04% | 186B | C+ | ||
-2.48% | 107B | C | ||
-4.24% | 67.44B | A | ||
+2.52% | 50.03B | B- | ||
+16.40% | 47.81B | B- | ||
+4.79% | 41.03B | B+ | ||
+3.16% | 26.85B | B | ||
+3.62% | 25.82B | A- | ||
-0.50% | 25.01B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NEOG Stock
- Ratings Neogen Corporation